DSM Biologics is building a portfolio of transformative technologies and services to revolutionize existing biopharmaceutical manufacturing processes.
We offer world-class technologies and manufacturing services to the biopharmaceutical market, incorporating mammalian cell lines as production platforms for recombinant proteins and monoclonal antibodies.
Faster time-to-market
With so much pressure in biopharmaceuticals linked to the time required for development phases, we can make a significant difference through the availability of many standardized steps and ready-to-use packages that are fine-tuned efficiently by our experienced personnel to reduce timelines, facilitate cost-effective development, and mitigate financial risk.
Our platform to support speed-to-market:
- XD®process technologies
- RHOBUST® (expanded bed absorption)
Expertise and capacity
Our Groningen plant is a recognized class-leading facility, where experienced personnel are knowledgeable in all commercial cell lines, including CHO, Hybridoma and PER.C6® cell line.
- Range of mammalian bioreactor sizes from 50L – 1,000L, combined with strong process and analytical development capabilities.
- Stainless steel and Single Use Bioreactors
Regulatory navigation
Proof of concept is a critical milestone in any biotech project in terms of establishing a good fit in a company’s product portfolio and attracting investment and/or acquisition at the earliest possible stage.
Our comprehensive customer support and considerable experience with regulation agencies helps lead to successful filings. All data and documentation required for cGMP batch material is provided in the required format.
